

References

I-109

1. Garcia-Alfonso P, Chaves M, Munoz A, et al. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study. *BMC Cancer*. 2015;15:327.
2. Chiang N, Chai T, Hsieh R, et al. A phase I dose-escalation study of PEPO2 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. *BMC Cancer*. 2016;1:907.
3. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med*. 2018;379:2395-2406.
4. Segar JM, Reed D, Stopeck A, et al. A Phase II study of irinotecan and etoposide as treatment for refractory metastatic breast cancer. *Oncologist*. 2019;24(12):1512.
5. Sobrero A, Lenz H, Eng C, et al. Extended RAS analysis of the Phase III EPIC trial: Irinotecan + cetuximab versus irinotecan as second-line treatment for patients with metastatic colorectal cancer. *Oncologist*. 2021;26(2):e261-e269.
6. Irinotecan Hydrochloride In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 3, 2017.
7. Clinical Pharmacology™ Compendium 2024. Tampa FL: Gold Standard, Inc. Irinotecan Hydrochloride.
8. Micromedex DrugDex Compendium®. 2024. Irinotecan Hydrochloride.
9. National Comprehensive Cancer Network (NCCN). Irinotecan hydrochloride. NCCN Drugs and Biologics Compendium®. 2024.
10. Camptosar® (Irinotecan hydrochloride) injection, for intravenous use [package insert]. Pharmacia & Upjohn CO. NY, NY. Revised 01/2022 .